Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2005 Jan 5;26(11):1728–1757. doi: 10.1016/j.clinthera.2004.11.014

Daptomycin: A cyclic lipopeptide antimicrobial agent

LilyAnn Jeu 1, Horatio B Fung 2,**
PMCID: PMC7133638  PMID: 15639687

Abstract

Objectives:

The aims of this article were: to summarize the pharmacology, pharmacokinetics, and efficacy ofdaptomycin; to explore its safety profile; and to discuss its current and potential roles as an antimicrobial therapy.

Methods:

A literature search was conducted using the MEDLINE (1966–August 2004) and InternationalPharmaceutical Abstracts (1970–August 2004) databases with the search terms daptomycin, LY146032, and lipopeptide antibiotics. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy and documents submitted to the US Food and Drug Administration were also reviewed.

Results:

Phase III study results suggest no difference in efficacy or tolerability between daptomycin 4 mg/kgIV QD and vancomycin or semisynthetic penicillins for complicated skin and skin-structure infections. Animal studies suggest daptomycin may be useful for the treatment of endocarditis. Daptomycin is not indicated for pneumonia, with poorer outcomes than conventional treatment It is available as an IV medication and exhibits 92% plasma protein binding in vitro. In healthy adult humans, daptomycin has a volume of distribution of 0.1 Ukg and a plasma elimination half-life of ∼9 hours, and is eliminated primarily by renal excretion (∼54%). In patients with reduced renal function, including those receiving hemodialysis and peritoneal dialysis, the dose interval should be 48 hours. No dosage adjustment appears to be necessary for mild to moderate hepatic impairment. The use of daptomycin in patients with severe hepatic impairment has not been assessed. The most commonly reported adverse events include constipation, nausea, injection-site reactions, headache, and diarrhea. Patients should also be monitored regularly for skeletal muscle toxicity.

Conclusions:

Daptomycin may be useful for complicated skin and skin-structure infections and gram-positive pathogens resistant to conventional antimicrobials. However, limited data are currently available for duration of treatment beyond 14 days and at doses >4 mg/kg QD.

Key words: daptomycin, LY146032, lipopeptide antibiotic, gram-positive resistance, skin and skin-structureinfections

References

  • 1.Fung H.B., Chang J.Y., Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs. 2003;63:1459–1480. doi: 10.2165/00003495-200363140-00003. [DOI] [PubMed] [Google Scholar]
  • 2.Nichols R.L. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother. 1999;44(Suppl A):19–23. doi: 10.1093/jac/44.suppl_1.19. [DOI] [PubMed] [Google Scholar]
  • 3.Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:624–626. [PubMed] [Google Scholar]
  • 4.Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46:765–766. [published correction appears in MMWR Morb Mortal Wkly Rep. 1997;46:851] [PubMed] [Google Scholar]
  • 5.Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46:813–815. [published correction appears in MMWR Morb Mortal Wkly Rep. 1997;46:851] [PubMed] [Google Scholar]
  • 6.Staphylococcus aureus resistant to vancomycin—United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:565–567. [PubMed] [Google Scholar]
  • 7.Chang S., Sievert D.M., Hageman J.C. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. Vol. 348. 2003. Vancomycin-Resistant Staphylococcus aureus Investigative Team; pp. 1342–1347. (N Engl J Med). [DOI] [PubMed] [Google Scholar]
  • 8.Whitener C.J., Park S.Y., Browne F.A. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis. 2004;38:1049–1055. doi: 10.1086/382357. [DOI] [PubMed] [Google Scholar]
  • 9.Vancomycin-resistant Staphylococcus aurus—Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:902. [published correction appears in MMWR Morb Mortal Wkly Rep. 2002;51:931] [PubMed] [Google Scholar]
  • 10.Tenover F.C., Weigel L.M., Appelbaum P.C. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother. 2004;48:275–280. doi: 10.1128/AAC.48.1.275-280.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Centers for Disease Control and Prevention (CDC) Vancomycin-resistant Staphylococcus aureus—New York, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:322–323. [PubMed] [Google Scholar]
  • 12.Das S.S., Anderson J.R., Macdonald A.A., Somerville K.W. Endocarditis due to high level gentamicin resistant Enterococcus faecium. J Infect. 1994;28:185–191. doi: 10.1016/s0163-4453(94)95680-4. [DOI] [PubMed] [Google Scholar]
  • 13.Kauffman C.A. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother. 2003;51(Suppl 3):iii23–iii3O. doi: 10.1093/jac/dkg273. [DOI] [PubMed] [Google Scholar]
  • 14.National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990–May 1999, issued June 1999. Am J Infect Control. 1999;27:520–532. doi: 10.1016/s0196-6553(99)70031-3. [DOI] [PubMed] [Google Scholar]
  • 15.Gonzales R.D., Shreckenberger P.C., Graham M.B. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet. 2001;357:1179. doi: 10.1016/S0140-6736(00)04376-2. [DOI] [PubMed] [Google Scholar]
  • 16.Herrero I.A., Issa N.C., Patel R. Nosocomial spread of linezolid-resistant, vancomycin resistant Enterococcus faecium. N Engl J Med. 2002;346:867–869. doi: 10.1056/NEJM200203143461121. [DOI] [PubMed] [Google Scholar]
  • 17.Auckland C., Teare L., Cooke F. Linezolid-resistant enterococci: Report of the first isolates in the United Kingdom. J Antimicrob Chemother. 2002;50:743–746. doi: 10.1093/jac/dkf246. [DOI] [PubMed] [Google Scholar]
  • 18.Tsiodras S., Gold H.S., Sakoulas G. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207–208. doi: 10.1016/S0140-6736(01)05410-1. [DOI] [PubMed] [Google Scholar]
  • 19.Schwartz M.D., Shive D.K., Shaikh Z.H. Delayed discovery of linezolid-resistant, vancomycin-resistant Enterococcus faecium: Lessons learned. Clin Infect Dis. 2004;38:155–156. doi: 10.1086/380465. [DOI] [PubMed] [Google Scholar]
  • 20.Rahim S., Pillai S.K., Gold H.S. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis. 2003;36:E146–E148. doi: 10.1086/374929. [DOI] [PubMed] [Google Scholar]
  • 21.Jones R.N., Della-Latta P., Lee L.V., Biedenbach D.J. Linezolid-resistant Enterococums faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRYAntimicrobial Surveillance Program. Diagn Microbial Infect Dis. 2002;42:137–139. doi: 10.1016/s0732-8893(01)00333-9. [DOI] [PubMed] [Google Scholar]
  • 22.Mutnick A.H., Biedenbach D.J., Jones R.N. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRYAntimicrobial Surveillance Program (1997–2000) Diagn Microbial Infect Dis. 2003;46:63–68. doi: 10.1016/s0732-8893(03)00012-9. [DOI] [PubMed] [Google Scholar]
  • 23.Center for Drug Evaluation and Research . October 22, 2004. Application number 21–572. Administrative Document(s)http://www.fda.gov/cder/foi/nda/2003/21_572_cubicin_admindocs_p1.pdf Available at: Accessed. [Google Scholar]
  • 24.Cubicin [package insert] Cubist Pharmaceuticals, Inc.; Lexington, Mass: 2003. [Google Scholar]
  • 25.Debono M., Abbott B.J., Molloy R.M. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: The synthesis and evaluation of daptomycin (LY146032) J Antibiot (Tokyo) 1988;41:1093–1105. doi: 10.7164/antibiotics.41.1093. [DOI] [PubMed] [Google Scholar]
  • 26.Debono M., Barnhart M., Carrell C.B. A21978C, a complex of new acidic peptide antibiotics: Isolation, chemistry, and mass spectral structure elucidation. J Antibiot (Tokyo) 1987;40:761–777. doi: 10.7164/antibiotics.40.761. [DOI] [PubMed] [Google Scholar]
  • 27.Silverman J.A., Perlmutter N.G., Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:2538–2544. doi: 10.1128/AAC.47.8.2538-2544.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Allen N.E., Hobbs J.N., Alborn W.E., Jr Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987;31:1093–1099. doi: 10.1128/aac.31.7.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Lakey J.H., Lea E.J. The role of acyl chain character and other determinants on the bilayer activity of A21978C an acidic lipopeptide antibiotic. Biochem Biophys Acta. 1986;859:219–226. doi: 10.1016/0005-2736(86)90217-8. [DOI] [PubMed] [Google Scholar]
  • 30.Lakey J.H., Maget-Dana R., Ptak M. The lipopeptide antibiotic A21978C has a specific interaction with DMPC only in the presence of calcium ions. Biochem Biophys Acta. 1989;985:60–66. doi: 10.1016/0005-2736(89)90104-1. [DOI] [PubMed] [Google Scholar]
  • 31.Lakey J.H., Ptak M. Fluorescence indicates a calcium dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry. 1988;27:4639–4645. doi: 10.1021/bi00413a009. [DOI] [PubMed] [Google Scholar]
  • 32.Eliopoulus G.M., Willey S., Reiszner E. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986;30:532–535. doi: 10.1128/aac.30.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Jung D., Rozek A., Okon M., Hancock R.E. Structural transitions as determinants of the action of the calcium dependent antibiotic daptomycin. Chem Biol. 2004;11:949–957. doi: 10.1016/j.chembiol.2004.04.020. [DOI] [PubMed] [Google Scholar]
  • 34.Micklefield J. Daptomycin structure and mechanism of action revealed. Chem Biol. 2004;11:887–888. doi: 10.1016/j.chembiol.2004.07.001. [DOI] [PubMed] [Google Scholar]
  • 35.Alborn W.E., Jr, Allen N.E., Preston D.A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother. 1991;35:2282–2287. doi: 10.1128/aac.35.11.2282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Allen N.E., Alborn W.E., Jr, Hobbs J.N., Jr Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 1991;35:2639–2642. doi: 10.1128/aac.35.12.2639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Canepari P., Boaretti M., Lleo M.M., Satta G. Lipoteichoic acid as a new target for activity of antibiotics: Mode of action of daptomycin (LY146032) Antimicrob Agents Chemother. 1990;34:1220–1226. doi: 10.1128/aac.34.6.1220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Boaretti M., Canepari P., Lleo M.M., Satta G. The activity of daptomycin on Enterococcus faecium protoplasts: Indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J Antimicrob Chemother. 1993;31:227–235. doi: 10.1093/jac/31.2.227. [DOI] [PubMed] [Google Scholar]
  • 39.Boaretti M., Canepari P. Identification of daptomycinbinding proteins in the membrane of Enterococcus hirae. Antimicrob Agents Chemother. 1995;39:2068–2072. doi: 10.1128/aac.39.9.2068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Canepari P., Boaretti M. Lipoteichoic acid as a target for antimicrobial action. Microb Drug Resist. 1996;2:85–89. doi: 10.1089/mdr.1996.2.85. [DOI] [PubMed] [Google Scholar]
  • 41.Laganas V., Alder J., Silverman J.A. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococms faecalis are not mediated by inhibition oflipoteichoic acid biosynthesis. Antimicrob Agents Chemother. 2003;47:2682–2684. doi: 10.1128/AAC.47.8.2682-2684.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wale L.J., Shelton A.P., Greenwood D. Scanning electron-microscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin. J Med Microbial. 1989;30:45–49. doi: 10.1099/00222615-30-1-45. [DOI] [PubMed] [Google Scholar]
  • 43.Conrad R.S., Howard M.J., Garrison R.C. The effects of daptomycin on chemical composition and morphology of Staphylococcus aureus. Proc Ohla Acad Sci. 1998;78:15–22. [Google Scholar]
  • 44.Woodworth J.R., Nyhart E.H., Jr, Brier G.L. Single-dose phamacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992;36:318–325. doi: 10.1128/aac.36.2.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Dvorchik B.H., Brazier D., DeBruin M.L., Arbeit R.D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318–1323. doi: 10.1128/AAC.47.4.1318-1323.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Lee B.L., Sachdeva M., Chambers H.E. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991;35:2505–2508. doi: 10.1128/aac.35.12.2505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Louie A., Kaw P., Liu W. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2001;45:845–851. doi: 10.1128/AAC.45.3.845-851.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Safdar N., Andes D., Craig W.A. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63–68. doi: 10.1128/AAC.48.1.63-68.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Caron F., Kitzis M.D., Gutmann L. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother. 1992;36:2611–2616. doi: 10.1128/aac.36.12.2611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Sakoulas G., Eliopoulos G.M., Alder J., Eliopoulos C.T. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1714–1718. doi: 10.1128/AAC.47.5.1714-1718.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Michiels M.J., Bergeron M.G. Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration. Antimicrob Agents Chemother. 1996;40:203–211. doi: 10.1128/aac.40.1.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Blaser J., Vergeres P., Widmer A.F., Zimmerli W. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother. 1995;39:1134–1139. doi: 10.1128/aac.39.5.1134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Wise R., Gee T., Andrews J.M. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 2002;46:31–33. doi: 10.1128/AAC.46.1.31-33.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Vaudaux P., Francois P., Bisognano C. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother. 2003;52:89–95. doi: 10.1093/jac/dkg277. [DOI] [PubMed] [Google Scholar]
  • 55.Pryka R.D., Novak R.M., Wagner D.K., Rodvold K.A. Clinical pharmacokinetics of daptomycin. DICP. 1990;24:255–256. doi: 10.1177/106002809002400309. [DOI] [PubMed] [Google Scholar]
  • 56.Woodworth J.R., Nybart E.H., Wolny J.D. Tobramycin and daptomycin disposition when co-administered to healthy volunteers. J Antimicrob Chemother. 1994;33:655–659. doi: 10.1093/jac/33.3.655. [DOI] [PubMed] [Google Scholar]
  • 57.Rybak M.J., Bailey E.M., Lamp K.C., Kaatz G.W. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis andbacteremia. Antimicrob Agents Chemother. 1992;36:1109–1114. doi: 10.1128/aac.36.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Dvorchik B., Arbeit R.D., Chung J. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799–2807. doi: 10.1128/AAC.48.8.2799-2807.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Dvorchik B., Sica D., Gehr T. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; San Diego, Calif: 2002. Pharmacokinetics (PK) and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease (ESRD) [CD-ROM] Abstract A-1387. [Google Scholar]
  • 60.Sica D.A., Gehr T., Dvorchik B.H. Abstracts of the 42nd Interscience Conference on AntimicrobialAgents and Chemotherapy. American Society for Microbiology; San Diego, Calif: 2002. Pharmacokinetics and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease. [CD-ROM] Abstract P-2257. [Google Scholar]
  • 61.Dvorchik B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol. 2004;44:715–722. doi: 10.1177/0091270004266619. [DOI] [PubMed] [Google Scholar]
  • 62.Dvorchik B., Damphousse D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol. 2004;44:612–620. doi: 10.1177/0091270004265646. [DOI] [PubMed] [Google Scholar]
  • 63.Center for Drug Evaluation and Research . October 22, 2004. Approval package for: Application number 21–572. Clinical pharmacology biopharmaceutics review.http://www.fda.gov/cder/foi/nda/2003/21_572_cubicin_bioPharmr_p1.pdf Available at: Accessed. [Google Scholar]
  • 64.Fuchs P.C., Barry A.L., Brown S.D. Daptomycin susceptibility tests: Interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbial Infect Dis. 2000;38:51–58. doi: 10.1016/s0732-8893(00)00164-4. [DOI] [PubMed] [Google Scholar]
  • 65.Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 6th ed. National Committee for Clinical Laboratory Standards; Wayne, Pa: 2003. [Google Scholar]
  • 66.Center for Drug Evaluation and Research . October 22, 2004. Approval package for: Application number 21-572. Micro biology review(s)http://www.fda.gov/cder/foi/nda/2003/21_572_cubicin_microbr_p1.pdf Available at: Accessed. [Google Scholar]
  • 67.Richter S.S., Kealey D.E., Murray C.T. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother. 2003;52:123–127. doi: 10.1093/jac/dkg288. [DOI] [PubMed] [Google Scholar]
  • 68.Alder J., Li T., Yu D. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrob Agents Chemother. 2003;47:3561–3566. doi: 10.1128/AAC.47.11.3561-3566.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Wise R., Andrews J.M., Ashby J.P. Activity of daptomycin against Gram-positive pathogens: A comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother. 2001;48:563–567. doi: 10.1093/jac/48.4.563. [DOI] [PubMed] [Google Scholar]
  • 70.Critchley I.A., Draghi D.C., Sahm D.F. Activity of daptomycin against susceptible and multidrugresistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother. 2003;51:639–649. doi: 10.1093/jac/dkg130. [DOI] [PubMed] [Google Scholar]
  • 71.Critchley I.A., Blosser-Middleton R.S., Jones M.E. Baseline study to determine in vitro activities of daptomycin against gram- positive pathogens isolated in the United States in 2000–2001. Antimicrob Agents Chemother. 2003;47:1689–1693. doi: 10.1128/AAC.47.5.1689-1693.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Streit J.M., Jones R.N., Sader H.S. Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother. 2004;53:669–674. doi: 10.1093/jac/dkh143. [DOI] [PubMed] [Google Scholar]
  • 73.Barry A.L., Fuchs P.C., Brown S.D. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother. 2001;45:1919–1922. doi: 10.1128/AAC.45.6.1919-1922.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.King A., Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother. 2001;48:219–223. doi: 10.1093/jac/48.2.219. [DOI] [PubMed] [Google Scholar]
  • 75.Howe R.A., Noel A.R., Tomaselli S. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; Washington, DC: 2003. Killing activity of daptomycin against vancomycin-intermediate Staphylococcus aureus (VISA) and hetero-VISA (hVISA) [CD-ROM] Abstract C1-1641. [Google Scholar]
  • 76.Bozdogan B., Esel D., Whitener C. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother. 2003;52:864–868. doi: 10.1093/jac/dkg457. [DOI] [PubMed] [Google Scholar]
  • 77.Klein J.D., Ludlam E., Steele-Moore L. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; San Diego, Calif: 2002. In vitro activity of ABT 773, telithromycin and daptomycin against group C and G streptococci. [CD-ROM] Abstract E-1894. [Google Scholar]
  • 78.Rybak M.J., Hershberger E., Moldovan T., Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother. 2000;44:1062–1066. doi: 10.1128/aac.44.4.1062-1066.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Cha R., Brown W.J., Rybak M.J. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitropharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2003;47:3960–3963. doi: 10.1128/AAC.47.12.3960-3963.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Akins R.L., Rybak M.J. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus,vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2001;45:454–459. doi: 10.1128/AAC.45.2.454-459.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Vance-Bryan K., Larson T.A., Rotschafer J.C., Toscana J.P. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1992;36:2334–2337. doi: 10.1128/aac.36.10.2334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Silva M., Jacobus N.V., Gorbach S.L. In vitro activity of LY146032 against gram-positive bacteria. Diagn Microbial Infect Dis. 1988;9:79–85. doi: 10.1016/0732-8893(88)90100-9. [DOI] [PubMed] [Google Scholar]
  • 83.Bingen E., Doit C., Lambert-Zechovsky N. Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model. Eur J Clin Microbial Infect Dis. 1991;10:1062–1065. doi: 10.1007/BF01984930. [DOI] [PubMed] [Google Scholar]
  • 84.Jain R., Schreckenberger P.C., Quinn J.P., Pendland S.L. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; Washington, DC: 2003. Bactericidal activity of daptomycin against clinical isolates of linezolid/vancomycin-resistant Enterococcus faecium. [CD-ROM] Abstract C1-1643. [Google Scholar]
  • 85.Pankuch G.A., Jacobs M.R., Appelbaum P.C. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates. Antimicrob Agents Chemother. 2003;47:3012–3014. doi: 10.1128/AAC.47.9.3012-3014.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Hanberger H., Nilsson L.E., Maller R., Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killingand postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991;35:1710–1716. doi: 10.1128/aac.35.9.1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Dandekar P.K., Tessier P.R., Williams P. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother. 2003;52:405–411. doi: 10.1093/jac/dkg337. [DOI] [PubMed] [Google Scholar]
  • 88.Miniter P.M., Patterson T.L., Johnson M.A., Andriole V.T. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother. 1987;31:1199–1203. doi: 10.1128/aac.31.8.1199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Rand K.H., Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother. 2004;53:530–532. doi: 10.1093/jac/dkh104. [DOI] [PubMed] [Google Scholar]
  • 90.Rice L.B., Eliopoulos C.T., Yao J.D. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn Microbial Infect Dis. 1992;15:173–176. doi: 10.1016/0732-8893(92)90045-u. [DOI] [PubMed] [Google Scholar]
  • 91.Watanakunakorn C. In vitro activity of LY 146032, a novel cyclic lipopeptide, alone and in combination with gentamicin or tobramycin against enterococci. J Antimicrob Chemother. 1987;19:445–448. doi: 10.1093/jac/19.4.445. [DOI] [PubMed] [Google Scholar]
  • 92.Rand K.H., Houck H.L. Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:2871–2875. doi: 10.1128/AAC.48.8.2871-2875.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Silverman J.A., Oliver N., Andrew T., Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001;45:1799–1802. doi: 10.1128/AAC.45.6.1799-1802.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Snydman D.R., McDermott L.A., Jacobus N.V. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; Chicago, Ill: 2001. Determination of synergistic effects of daptomycin with gentamicin or in vitro effect of beta lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and time-kill kinetics. [CD-ROM] Abstract E-533. [Google Scholar]
  • 95.Kaatz G.W., Seo S.M. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; Chicago, Ill: 2001. Analysis of the mechanisms of daptomycin resistance in Staphylococcus aureus. [CD-ROM] Abstract C1-1803. [Google Scholar]
  • 96.Hindes R.G., Willey S.I.T., Eliopoulos G.M. Treatment of experimental endocarditis caused by a β-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1989;33:1019–1022. doi: 10.1128/aac.33.7.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Kaatz G.W., Seo S.M., Reddy V.N. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990;34:2081–2085. doi: 10.1128/aac.34.11.2081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Cantoni L., Glauser M.P., Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role oftest conditions in this determination. Antimicrob Agents Chemother. 1990;34:2348–2353. doi: 10.1128/aac.34.12.2348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Luu Q.N., Buxton T.B., Nelson D.R., Rissing J.P. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbial Infect Dis. 1989;8:562–563. doi: 10.1007/BF01967482. [DOI] [PubMed] [Google Scholar]
  • 100.Vaudaux P., Schaad H., Francois P. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; San Diego, Calif: 2002. Efficacy of a high-dose regimen of daptomycin compared to oxacillin and vancomycin in the therapy of experi mental foreign body infection due to methicillin-suscephble Staphylococcus aureus. [CD-ROM] Abstract 1904. [Google Scholar]
  • 101.Wood C.A., Finkbeiner H.C., Kohlhepp S.J. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1989;33:1280–1285. doi: 10.1128/aac.33.8.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Sapico F.L., Ginunas V.J., Canawati H.N., Montgomerie J.Z. LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelo nephritis in the rat model. Antimicrob Agents Chemother. 1988;32:81–83. doi: 10.1128/aac.32.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Bush L.M., Boscia J.A., Kaye D. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1988;32:877–881. doi: 10.1128/aac.32.6.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Ramos M.C., Grayson M.L., Eliopoulos G.M., Bayer A.S. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endo carditis caused by penicillin-resistant enterococci. Antimicrob Agents Chemother. 1992;36:1864–1869. doi: 10.1128/aac.36.9.1864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Mader J.T., Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureusosteomyelitis in rabbits. Antimicrob Agents Chemother. 1989;33:689–692. doi: 10.1128/aac.33.5.689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Haworth C.S., Sobieski M.W., Scheld W.M., Park T.S. Staphylococcus aureus ventriculitis treated with singledose intraventricular vancomycin or daptomycin (LY146032): Bacterial and antibiotic kinetics in hydrocephalic rabbits. Antimicrob Agents Chemother. 1990;34:245–251. doi: 10.1128/aac.34.2.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Kephart P.A., Esposito A.L. Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1988;21:33–39. doi: 10.1093/jac/21.1.33. [DOI] [PubMed] [Google Scholar]
  • 108.Verghese A., Haire C., Franzus B., Smith K. LY146032 in a hamster model of Staphylococcus aureus pneumonia effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy. 1988;34:497–503. doi: 10.1159/000238615. [DOI] [PubMed] [Google Scholar]
  • 109.Dong M.Y., Chang T.W., Gorbach S.L. Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032. Antimicrob Agents Chemother. 1987;31:1135–1136. doi: 10.1128/aac.31.7.1135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Li T., Yu D., Mortin L.I. Abstracts of the IDSA 40th Annual Meeting. Infectious Diseases Society of America; Chicago, Ill: 2002. Rapid bactericidal action of daptomycin against septicemia induced by gram positive bacteria in mice. [CD-ROM] Abstract 50. [Google Scholar]
  • 111.Smith K., Cobbs G., Dill R. Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model. Chemotherapy. 1990;36:428–434. doi: 10.1159/000238800. [DOI] [PubMed] [Google Scholar]
  • 112.Dougherty S.E.E., Hentges D.J., Casey S.W., Thal W.R. Impact of LY146032 on Streptococcus (Enterococcus) faecalis translocation in mice. Antimicrob Agents Chemother. 1988;32:337–340. doi: 10.1128/aac.32.3.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Beauchamp D., Gourde P., Simard M., Bergeron M.G. Subcellular distribution of daptomycin given alone or with tobramycin in renal proximal tubular cells. Antimicrob Agents Chemother. 1994;38:189–194. doi: 10.1128/aac.38.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Gurnani K., Khouri H., Couture M. Molecular basis of the inhibition of gentamicin nephrotoxicity by daptomycin; an infrared spectroscopic investigation. Biochem Biophys Acta. 1995;1237:86–94. doi: 10.1016/0005-2736(95)00082-e. [DOI] [PubMed] [Google Scholar]
  • 115.Carrier D., Khalil M.B., Kealey A. Modulation of phospholipase A2 activity among aminoglycosides and daptomycin: A Fourier transform infrared spectroscopy study. Biochemistry. 1998;37:7589–7597. doi: 10.1021/bi971793d. [DOI] [PubMed] [Google Scholar]
  • 116.Couture M., Simard M., Gourde P. Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin. Antimicrob Agents Chemother. 1994;38:742–749. doi: 10.1128/aac.38.4.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Center for Drug Evaluation and Research . October 22, 2004. Approval package for: Application number 21–572. Medical Review(s)http://www.fda.gov/cder/foi/nda/2003/21_572_cubicin_medr_p1.pdf Available at: Accessed. [Google Scholar]
  • 118.Arbeit R.D., Maki D., Tally I.T., Daptomycin 98-01 and 99-01 Investigators The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681. doi: 10.1086/420818. [DOI] [PubMed] [Google Scholar]
  • 119.Rodin D., Arbeit R.D., 99-01 Investigators . Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; Chicago, Ill: 2001. Clinical significance of dual infection (DI) with Staphylococcus aureus (SA) and hemolytic streptococci (hStr) in com plicated skin and soft tissue infections (cSSTI): Results from daptomycin (DAP) trial 99-01. [CD-ROM] Abstract L-1482. [Google Scholar]
  • 120.Matthews P.A., Debrun M.E. Abstracts of the IDSA 39th Annual Meeting. Infectious Diseases Society of America; San Francisco, Calif: 2001. Faster resolution of clinical signs (CSx) in complicated skin and soft tissue infection (cSSTI) by daptomycin (DAP) vs standard therapy (STND) in arandomized, blinded, comparative study. [CD-ROM] Abstract 112. [Google Scholar]
  • 121.Snydman D.R. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; Toronto, Ont: 2000. Daptomycin. [CD-ROM] Abstract 1125. [Google Scholar]
  • 122.Golan Y., Poutsiaka D.D., Tozzi S. Daptomycin for line-related Leuconostoc bacteraemia. J Antimicrob Chemother. 2001;47:364–365. doi: 10.1093/jac/47.3.364. [DOI] [PubMed] [Google Scholar]
  • 123.Oleson F.B., Jr, Berman C.L., Kirkpatrick J.B. Oncedaily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44:2948 2953.. doi: 10.1128/aac.44.11.2948-2953.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Knapp A.G., Tally I.T., Arbeit R.D. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; Washington, DC: 2003. Skeletal muscle effects in patients receiving once-daily daptomycin (DAP) for complicated skin and skin structure infec tion (cSSSI) [CD-ROM] Abstract L-736. [Google Scholar]
  • 125.Kreft B., de Wit C., Krech R. Experimental studies on nephrotoxicity and pharmacokinetics of LY146032 (daptomycin) in rats. J Antimicrob Chemother. 1990;25:635–643. doi: 10.1093/jac/25.4.635. [DOI] [PubMed] [Google Scholar]
  • 126.Thomson Medical Economics; Montvale, NJ: 2004. (Drug Topics Red Book). [Google Scholar]
  • 127.Hermsen E.D., Hovde L.B., Hotchkiss J.R., Rotschafer J.C. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother. 2003;47:3764–3767. doi: 10.1128/AAC.47.12.3764-3767.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Therapeutics are provided here courtesy of Elsevier

RESOURCES